Systemic Lupus Erythematosus is one of the classic examples of autoimmune diseases among human beings and is a rare disease in Pakistani population. Clinically it is a quite diverse and complicated autoimmune disease in a sense that it involves multiple organs of the body and mimics with other diseases as well. Th is study focused on the distribution of HLA alleles in SLE patients with ACE I/D Polymorphism. A total of  individuals were enrolled in this study,  were the SLE patients who fulfi lled revised ACR criteria and  were the healthy controls. Mean age of SLE patients at diagnosis was . ± . years (Range: - years). ACE gene I/D polymorphism was performed by nested PCR and DNA based HLA typing technique was used. ACE gene I/D polymorphism of Intron was studied and found to be involved in the activity of SLE. Th ere is high frequency
INTRODUCTION
Lupus is one of the examples of autoimmune diseases among human beings. Th ere are diff erent types of lupus like cutaneous lupus, neonatal lupus, drug induced lupus but the most important one is Systemic lupus Erythematosus (SLE). SLE is a chronic illness and can prove to be fatal when it involves multiple organs of the body like brain, heart, kidney, skin. Th is is a multisystem disorder that occurs with the contribution of hormonal, genetic, immunological, and environmental factors. Immunogenetic factors are important in two ways; one by infl uencing the disease penetration and secondly by the production of Autoantibodies [] . Angiotensin converting Enzyme (ACE) gene contains a polymorphism based on the presence (Insertion I) or absence (deletion D) of a non-sense fragment. In humans, I/D polymorphism is located in Intron  of the angiotensin gene. Th is polymorphism is responsible for the ACE activity level which increases -fold in homozygous deletion carriers (D/D) as compared to homozygous insertion carriers (I/I) while I/D carriers show intermediate ACE activity. Th e infl uence of ACE I/D polymorphism on pathological conditions mediated through ACE activity is found to be associated with various diseases and one of them is SLE [] . Similarly Major Histocompatibility Complex (MHC) also shows a high degree of polymorphism and these polymorphisms are inherited, lead to autoimmune disorders like SLE. Th is study mainly focused on the distribution of HLA alleles in SLE patients with ACE I/D Polymorphism [] .
MATERIALS AND METHODS

Patients
A total of  individuals were enrolled in this study. Of the ,  were the SLE patients who fulfilled revised ACR criteria and  were the healthy controls [] .
Procedures
Blood samples from lupus patients were collected from Rheumatology and Nephrology Departments of different hospitals of Lahore. Consents of the patients were obtained on a consent form and Ethical Committee (Uni-versity of the Punjab), approved the study design. Physical, biochemical and hematological parameters were also collected. Hematological parameters like Complete Blood Count (CBC), prothrombin time and Biochemical parameters like complete urine analysis, serum urea, and creatinine were measured only in those cases where history of the patient suggested. Immunological Parameters (ANA, ds-DNA, Anti-Sm, Anti-SSAo, La, nDNA, Anti-histone) were measured by using Indirect ELISA Technique (Orgentec kits). Nested PCR for ACE I/D Polymorphism and DNA based HLA typing was performed for studying  alleles at locus A,  alleles at locus B and  alleles at locus DRB.
Statistical analysis
Statistical analysis was done by using SPSS ver .
RESULTS
Autoantibodies (anti-dsDNA, anti-Sm, anti-Rib-P, anti-SSA, anti-SSB, anti-histone, anti-MCV), cytokine (IL-), and immunoglobulins (IgA, IgM, IgG) were found to be correlated with one another in one way or other. Anti-SSB and anti-SSA were the autoantibodies that were found to co-exist in the sera of SLE patients, there was a positive correlation between anti-SSA and anti-SSB but it was not found to be statistically significant (r = ., p > .). Interestingly a signifi cant positive correlation was found between anti-histone and anti-SSB (r = ., p > .). A signifi cant positive correlation was found between anti-MCV antibodies and IL- indicating that if the amount of anti-MCV antibodies increases, the level of IL- also increases (Table ) . SLE patients (.) which were positive for ribosomal P antibodies were also found to be positive for anti-dsDNA antibodies. Of these ribosomal P antibodies positive patients, . were the patients of lupus nephritis and here lupus nephritis was defi ned by high creatinine level and proteinuria. In this study, a positive correlation was found between ribosomal P antibodies and lupus nephritis represented by a linear line Anti-dsDNA (Figure b) . HLA alleles found in present SLE subjects with ACE II and ID genotypes are listed inTable- and in Table  Figure c) . Th ese are the HLA alleles that showed overall significant association with SLE patients. We also analyzed distribution of HLA-A, -B, -DRB alleles in SLE patients with various disease phenotypes like skin involvement, lupus nephritis, rheumatoid arthritis or a combination of them. HLA-A* was the most common allele found in SLE patients with the involvement of skin. HLA-A* and -A* were common in SLE patients with arthritis while HLA-A* and -A* were commonly found in SLE patients with nephritis ( Figure a) . On the other hand, HLA-B* was the most common allele found in SLE patients with the involvement of skin. HLA-B* and -B* were common in SLE patients with arthritis while -B* was commonly found in SLE patients with nephritis. As we know that SLE is a multifactorial disease; the Figure b represents that the HLA-B* allele is commonly found in SLE patients with 
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the combination skin and nephritis. SLE patients involving both skin and kidney had an allele HLA-DRB* common in them but we can't comment on other manifestations as the differences were not appreciable (Figure c) .
DISCUSSION
Circulating antinuclear antibodies were commonly seen in SLE patients and their presence formed part of the diagnosis. In this study, the most aff ected organs were skin, kidney 
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and joints while eye, heart were also found to be involved. SLE was a complex cascade of autoantibodies, complement components, and of immunoglobulins. Rheumatoid arthritis was the most common autoimmune infl ammatory arthritis found commonly as one of the clinical manifestations of SLE. Circulating autoantibodies like ANA (χ  = ., p < .), anti-dsDNA (χ  = ., p < .), anti-SSA (t= ., p < .), anti-histone (t= ., p < .) and antiRib-P (t= ., p= .) were found to be signifi cantly associated with SLE while anti-Sm (t=., p= .) and anti-SSB (t= ., p= .) were found to be insignifi cantly associated with SLE. Serum levels of immunoglobulins and of complement components were estimated. IgG and IgM levels were signifi cantly high in SLE patients while low level of C was found in most of the SLE patients. Interestingly it was noted that anti-MCV autoantibodies (t= ., p = .) were not only associated with rheumatoid arthritis but also with SLE. Cytokines are believed to play an important role in SLE but cytokine IL- was found to be associated not signifi cantly with SLE in Pakistani SLE patients (χ  = ., p = .). A signifi cant positive correlation was found between anti-MCV antibodies and IL-, one of the reasons is that IL- is a cytokine produced by rheumatoid synovium. Gerli et al. [] as well as Massardo et al. [] could not fi nd any correlation between ribosomal P antibodies and lupus nephritis while Reichlin and Marianne [] found a strong association of anti dsDNA and of anti ribosomal P antibodies with lupus nephritis. No doubt autoantibodies are involved in the pathogenicity of lupus as it is an autoimmune disease for example levels of anti-dsDNA antibodies are directly proportional to lupus nephritis severity. But recently Macedo et al. [] has proved the protective role of ribosomal P antibodies, according to him SLE patients with ribosomal P antibodies alone have a tendency of better renal survival as compared to other lupus patients (anti-Rib P+/anti-dsD-NA+; anti-Rib P-/anti-dsDNA). In the present study, SLE patients (.) which were positive for ribosomal P antibodies were also found to be positive for anti-dsDNA antibodies. A positive correlation was found between ribosomal P antibodies and lupus nephritis but it was not signifi cant. A number of syndromes overlapped with SLE like Sjogren's syndrome, Scleroderma, Rheumatoid arthritis, Antiphospholipid syndrome and Budd Chiari syndrome. Boier et al. [] found a positive association of photosensitivity, oral ulcer and of Raynaud's phenomenon with SLE overlapping with Sjogren's syndrome but a negative association of lupus nephritis with SLE having Sjogren's syndrome [] . In the present study, Raynaud's Phenomenon () and Photosensitivity () were commonly seen in SLE patients with Sjogren's syndrome while oral ulcer and lupus nephritis were not found in these patients. Eye involvement and Raynaud's phenomenon are commonly seen in SLE patients with Scleroderma [] . Similarly, in the present study, SLE patients with Scleroderma, Raynaud's phenomenon () and Photosensitivity () had common manifestations of lupus but organs like eye, kidneys were not found to be involved in them. However, in addition to vasculitis in SLE patients with secondary antiphospholipid syndrome, photosensitivity was also found in one of such patient. So a common feature was photosensitivity that fl ares up not in SLE alone but also in Scleroderma, Sjogren's syndrome and in Raynaud's phenomenon overlapping with SLE. According to Sato et al. [] , SLE patients homozygous for insertion polymorphism display higher serum level of ds-DNA antibodies and thus showed significant increase in SLE activity. In the present study,  of the SLE patients with II and ID genotype showed higher serum levels of ds-DNA antibodies, similarly, . of the SLE patients homozygous for deletion polymorphism were also positive for dsDNA antibodies, thus indicating lupus activity in all of the subjects with ACE II, ID, and DD genotypes. Uhm et al. [] found that individuals with DD genotype had a very low level of anti-Sm antibodies and thus found to be less associated with Raynaud's phenomenon but in this study .  of the SLE patients with DD genotype had higher levels of anti-Sm antibodies and had the obvious symptoms of Raynaud's phenomenon. Th e frequency of DD genotype was found to be higher in SLE patients with Lupus Nephritis, Sjogren's syndrome, Rayanud's phenomenon and with Rheumatoid arthritis. So one can say that ACE I/D polymorphism is might be involved in syndromes overlapping with SLE. Complement levels indicate lupus exacerbation especially C and C levels which are found to be signifi cantly associated with lupus nephritis [] . In this study, levels of C and C were studied in SLE patients with diff erent ACE genotypes. Low C particularly C were found to be more depressed in SLE patients with DD genotype. Hong et al. [] found IgA mesangial deposition in renal biopsy specimens of lupus nephritis patients. In the present study, all SLE patients with diff erent ACE genotypes had a normal IgA level. Th ere are several studies of ACE I/D polymorphism in relation to HLA-DR in several diseases like Sarcodosis [] but we could not fi nd any previous data on such relation in SLE patients. Th e present study was population based, here patient and control samples were collected from the same relatively homogenous population. Th e main advantage is that such studies are easy to perform and make it possible to establish the risk factors of individuals with certain HLA types. Th is study confi rmed and extended the association of SLE with certain MHC alleles in Pakistani population. Th is study will open up new opportunities to improve diagnosis and treatment of SLE patients in this population, thus new therapies can be developed.
